
Erasca Inc (ERAS) Stock Forecast & Price Target
Erasca Inc (ERAS) Analyst Ratings
Bulls say
Erasca is a clinical-stage precision oncology company that is focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs and one discovery-stage program, with key milestones on track for 2026 and 2027. The company's recent earnings report confirmed the 1H26 update for ERAS-0015 with both US and China data, and the KOL discussion highlights the potential for Erasca's pan-RAS inhibitor to differentiate from existing competitors in terms of potency, safety, and efficacy. Topline data for ERAS-0015 and ERAS-4001 in 2027 will be key catalysts for the company.
Bears say
Erasca is currently facing significant challenges in its clinical development due to limited clinical evidence and unclear target engagement, posing significant risks for its future financial stability. With increased competition and potential regulatory hurdles in its pan-RAS approach, the company's relatively high valuation, and limited data, its future as a key player in the RAS/MAPK pathway may be uncertain, making it a risky investment option.
This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.
Erasca Inc (ERAS) Analyst Forecast & Price Prediction
Start investing in Erasca Inc (ERAS)
Order type
Buy in
Order amount
Est. shares
0 shares